Abstract: A method for modulating the specific activitiy of a target protein which is being purified. A controller protein is added to the target protein prior to conducting a final purification step in a purification process.

Abstract: The invention pertains to pure, native dystrophin of mammalian skeletal muscle and a method of purifying dystrophin from mammalian skeletal muscle. The invention further pertains to a method of diagnosing muscular dystrophy by detecting the loss or abnormal structure of pure, native dystrophin from mammalian skeletal muscle. The detection of a loss of dystrophin or an abnormal structure of dystrophin is indicative of muscular dystrophy.

Abstract: The subject invention provides a pharmaceutical composition, which comprises an amount of calreticulin effective for blocking or preventing thrombosis in a subject, causing substantially no defect or no defect in normal hemostasis, and a pharmaceutically effective carrier. The subject invention provides a method for blocking or preventing thrombosis in a subject, causing substantially no defect or no defect in normal hemostasis, which method comprises administering calreticulin to the subject in an amount effective for blocking or preventing thrombosis. The subject invention provides a pharmaceutical composition, which comprises calreticulin in combination with an other antithrombotic agent, in an amount and proportion effective for enhancing the action of the other antithrombotic agent, to prevent clotting or dissolve clots which have already formed.

Abstract: A kit and method of non-destructively radiolabelling a biomolecule substrate by halogenation, including the steps of: a) reacting a secondary amine with a chlorinating agent to produce an N-chloro secondary amine, (b) reacting the N-chloro secondary amine with a salt of a radiolabelled halogen to produce a radiolabelled halogenating agent, (c) reacting a solution of the biomolecule substrate with the radiolabelled halogenating agent, and (d) recovering a radiohalogenated biomolecule from the reaction of step (c). The kit and method allow for more complete iodination with a lessening of side reactions such as decomposition of the biomolecule substrate to be labelled.

Abstract: This invention relates to a process for the recovery of .alpha.-lactalbumin and/or .beta.-lactoglobulin enriched whey protein concentrate from a whey protein product. The process comprises the following steps:a) incubating a solution comprising whey protein product with a calcium-binding ionic exchange resin in its acid form to initiate the instabilization of .alpha.-lactalbumin,b) adjusting the pH of the treated protein product solution to a value between 4.3 and 4.8, after separation of the resin,c) incubating the protein product solution at a temperature between 10 and 50.degree. C. to promote the flocculation of .alpha.-lactalbumin,d) fractionating the proteins in the protein product solution at pH 4.3-4.8, providing an .alpha.-lactalbumin enriched fraction and a .beta.-lactoglobulin enriched fraction,e) raising the pH of the .alpha.-lactalbumin enriched fraction sufficiently to solubilize the .alpha.-lactalbumin fraction, andf) optionally raising the pH of the .beta.

Abstract: The method for preparing high grade gelatin with a specific methionine content and with reduced methionine variability from batch to batch and within a single extraction includes controlling the amount of and variability of oxidant present during processing of bone stock into gelatin. Such controls include control of oxidant concentration and range in process water, control of volume of process water used in gelatin-making process and restriction of the range of gelatin extracts used in the product gelatin. Once the aim level of oxidant has been set, the total range of oxidant around the set point should be less than 220 meq per 100 kg dry bone.

Abstract: Organofunctional silicone chains having an organic moiety on at least one end of the chains, are covalently linked to free amino groups of proteins by the organic moieties to provide a useful ingredient for cosmetic formulations.

Abstract: The invention relates to a method of producing virus-safe highly purified factor VIII. The method includes a combination of the following measures:a) chromatographic purification of a factor VIII-containing fraction,b) tenside treatment of factor VIII in an aqueous solution at a tenside/protein ratio of from 1:1 to 1000:1, andc) heat treatment of the factor VIII preparation in the solid state.

Abstract: The present invention is directed to a stabilized keyhole limpet hemocyanin (KLH) composition in which (i) its intact non-degraded subunit is approximately 400,000 in molecular weight based on SDS-PAGE analysis; and (ii) are contained at least about 50% didecameric or higher KLH multimers, based on sedimentation-equilibrium and/or sedimentation-velocity ultracentrifugation analyses. The KLH composition is stabilized at 4.degree. C. by dissolving and storing it in an isotonic buffer preferably containing calcium and magnesium. It is critical that the KLH not have been frozen or lyophilized during its preparation or storage. The KLH composition demonstrates enhanced immunogenic activity, particularly enhanced anti-tumor activity, which is reduced if the KLH is frozen or lyophilized. The KLH composition of the present invention exhibits enhanced anti-tumor activity in a murine bladder tumor model and thereby represents a new and useful anti-tumor immunotherapeutic agent.

Abstract: A composition intended for use in dietetics, reanimation and therapeutics is provided. The composition includes lactoserum minipeptides, casein minipeptides, and casein minipeptides without phosphopeptides. The selected minipeptides are present in an amount sufficient to assure a proper balance between a level of sulfur-containing amino acids and a level of phosphorus bound to proteins.

Abstract: An enteral nutritional product for persons infected with human immunodeficiency virus contains a soy protein hydrolysate having a degree of hydrolysis in the range of about 14 to 17 and a molecular weight partition, as determined by size exclusion chromatography, wherein 30-60% of the particles have a molecular weight in the range of 1500-5000 Daltons. The nutritional product also contains a source of intact protein. The nutritional product has a ratio, by weight, of n-6 to n-3 fatty acids of about 1.3:1 to 2.5:1. The nutritional product also contains a source of dietary fiber.

Abstract: Enhancement of the method and oral compositions for inhibiting adherence of Streptococcus pyogenes to pharyngeal and oral mucosa cells by treating these areas with a glycoconjugate comprising an oligosaccharide linked to a carrier. The oligosaccharide should have at least one fucose moiety or a galatose moiety which is free of digalactose and N-acetylneuraminyl lactose. The carrier may include albumins, starch or synthetic polymers.

Abstract: The invention relates to a novel process for preparing immunoconjugates consisting of haptens which are sparingly soluble or insoluble in aqueous solution and proteins/polypeptides using special solvents, in particular diethylene glycol monoalkyl ethers.

Abstract: Curculin C of the present invention has an intrachain disulfide linkage formed between the 29th cysteine residue and the 52nd cysteine residue and interchain disulfide linkages formed between the 77th cysteine residues of two curculin C monomer chains and between the 109th cysteine residues of two curculin C monomer chains, thus giving a dimer, and the monomer has an amino acid sequence as specified in SEQ ID No: 1.

Abstract: Polypeptide compositions for inter alia SMS are provided containing a monosaccharide/sugar alcohol and/or a polyoxyalkylene ether having enhanced resorption properties for oral or rectal administration.

Abstract: New methods are provided for the identification and purification of proteins from plants with an inhibitory effect on pathogens and/or pests, such as insects, nematodes, fungi, and bacteria, using a combination of non-denaturing protein fractionation techniques on leaf-extracts of plants which were treated to develop induced resistance and an antipathogenic assay. Also provided are antifungal proteins obtained by the method, recombinant nucleotide sequences encoding the proteins, as well as plants with reduced susceptibility to fungi due to production and desired targeting of the proteins in the plant.

Abstract: An antithrombin III is described comprising a lyophilized powder of antithrombin III and a polyoxyethylene glycol sorbitan alkyl ester as well as a kit composed of a container wherein a lyophilized powder of antithrombin III is placed and a solvent for the powder, characterized in that a polyoxyethylene glycol sorbitan alkyl ester is added to either or both of the powder and the solvent. The preparation has a high solubility in water by retaining its activity.

Abstract: Primary-toxic chemical compounds with a molecular weight of less than 12000 Daltons, which may be isolated from plant material and which are potential IgE-binding allergens causing immediate-type allergy in predisposed individuals; methods for their isolation and their use for clinical purposes.

Abstract: A method of using IL-4, the use of IL-4 for the manufacture of a medicament and pharmaceutical compositions containing IL-4, for treating solid tumor growth by systemically injecting IL-4, such as hIL-4 or recombinant E. coli--derived IL-4, into mammals afflicted with solid tumors is disclosed.

Abstract: A pyridoxylated hemoglobin is prepared in a one-step, one-container process from red blood cells or essentially stroma-free hemoglobin by suspending the cells or hemoglobin in an aqueous medium, adding a chemical reducing agent and a pyridoxylating agent, and heating the reaction mixture obtained at a certain temperature for a certain time, while maintaining reducing conditions in the reaction medium.